Home Contact Us 中文 English
Yourlocation:Home >News> Clinical effect of compound azinomide combined with trimebutine maleate in the treatment of functional dyspepsia

Clinical effect of compound azinomide combined with trimebutine maleate in the treatment of functional dyspepsia

Time:2017/8/3 17:12:08

To study the clinical efficacy and safety of compound azinomide and trimebutine maleate in the treatment of functional dyspepsia.

A total of 84 patients with functional dyspepsia were enrolled from October 2015 to September 2016. They were divided into two groups according to the randomized grouping method: 42 cases in the experimental group and the control group. The control group was given 0.2g of trimebutine maleate before the meal. The experimental group was treated with compound azazmitam enteric-coated tablets 150mg + trimebutine maleate 0.2g in the meal or after the meal. The above drugs are oral, 3 times /d.

Compared with the control group, the total effective rate was 92.86% in the experimental group, which was significantly higher than that in the control group (76.19%). There was no significant adverse reaction (p <0.05).

Compound saloxidide combined with trimebutine maleate in the treatment of functional dyspepsia is effective and has no obvious adverse reaction and is worthy of popularization in the future clinical work.